BRUSSELS, Jan 17 (Reuters) - The EU regulator said on Monday it was pressing pharmaceutical companies for more information on their patent deals with generic companies to make sure there is no delay in cheaper drugs coming to market.
The move is the latest in a series of EU crackdowns on possible anti-competitive practices in the pharmaceutical sector after a 2009 patents enquiry pointed to significant risks for European consumers, the Commission said.
It did not mention any company it requested information from, but Britain's AstraZeneca PLC (AZN.L) and GlaxoSmithKline (GSK.L), France's Sanofi-Aventis (SASY.PA) and Novartis (NOVN.VX) and Roche (ROG.VX) of Switzerland said last year the Commission had contacted them about drug patent settlements.
Monday, January 17, 2011
EU ramps up drugs patent settlements scrutiny | Reuters
via reuters.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment